Journal of Nursing ›› 2023, Vol. 30 ›› Issue (17): 39-44.doi: 10.16460/j.issn1008-9969.2023.17.039
Previous Articles Next Articles
Defining polypharmacy based on Rodgers’ evolutionary concept analysis
CHEN Ran, LI Chun-yu, LI Mei-qian
- School of Nursing, Yanbian University, Yanji 133002, China
CLC Number:
- R197.323.2
| [1] 王丽敏, 陈志华, 张梅,等. 中国老年人群慢性病患病状况和疾病负担研究[J]. 中华流行病学杂志,2019,40(3):277-283. DOI:10.3760/cma.j.issn.0254-6450.2019.03.005. [2] World Health Organization. Medication safety in polypharmacy[EB/OL].(2019-06-20)[2023-02-02].https://www.who.int/publications/i/item/WHO-UHC-SDS-2019.11. [3] Guillot J, Maumus-Robert S, Bezin J.Polypharmacy: a general review of definitions, descriptions and determinants[J]. Therapie, 2020, 75(5):407-416. DOI:10.1016/j.therap.2019.10.001. [4] 李晴歌, 胡嘉乐, 郑窑文,等. 概念分析方法及在护理研究中的应用[J]. 护理学杂志,2018,33(4):100-102. DOI:10.3870/j.issn.1001-4152.2018.04.100. [5] 李依霖, 康晓凤, 邢海英,等. PubMed数据库中护理相关概念分析的计量学研究[J].护理学报,2016,23(23):6-10. DOI:10.16460/j.issn1008-9969.2016.23.006. [6] Rodgers BL.Concepts, analysis and the development of nursing knowledge: the evolutionary cycle[J]. J Adv Nurs,1989,14(4):330-335. DOI:10.1111/j.1365-2648.1989.tb03420.x. [7] Payne RA.The epidemiology of polypharmacy[J]. Clin Med (Lond),2016,16(5):465-469. DOI:10.7861/clinmedicine.16-5-465. [8] Stewart RB.Polypharmacy in the elderly: a fait accompli?[J]. DICP,1990,24(3):321-323.DOI:10.1177/106002809002400320. [9] Bikowski RM, Ripsin CM, Lorraine VL.Physician-patient congruence regarding medication regimens[J]. J Am Geriatr Soc,2001,49(10):1353-1357.DOI:10.1046/j.1532-5415.2001.49265.x. [10] WHO Centre for Health Development. A glossary of terms for community health care and services for older persons[EB/OL].(2004-02-02)[2023-02-02].https://www.who.int/iris/handle/10665/68896. [11] Dreischulte T, Shahid F, Muth C, et al.Prescribing cascades: how to detect them, prevent them, and use them appropriately[J]. Dtsch Arztebl Int,2022,119(44):745-752. DOI:10.3238/arztebl.m2022.0306. [12] 中国老年保健医学研究会老年内分泌与代谢病分会, 中国毒理学会临床毒理专业委员会. 老年人多重用药安全管理专家共识[J]. 中国全科医学,2018,21(29):3533-3544. DOI:10.12114/j.issn.1007-9572.2018.00.225. [13] Fincke BG, Snyder K, Cantillon C, et al.Three complementary definitions of polypharmacy: methods, application and comparison of findings in a large prescription database[J]. Pharmacoepidemiol Drug Saf, 2005, 14(2):121-128. DOI:10.1002/pds.966. [14] Nobili A, Franchi C, Pasina L, et al.Drug utilization and polypharmacy in an Italian elderly population: the EPIFARM-elderly project[J]. Pharmacoepidemiol Drug Saf,2011,20(5):488-496. DOI:10.1002/pds.2108. [15] Bjerrum L, Søgaard J, Hallas J, et al.Polypharmacy: correlations with sex, age and drug regimen.A prescription database study[J]. Eur J Clin Pharmacol,1998,54(3):197-202. DOI:10.1007/s002280050445. [16] Masnoon N, Shakib S, Kalisch-Ellett L, et al.What is polypharmacy? A systematic review of definitions[J]. BMC Geriatrics,2017,17(1):230.DOI:10.1186/s12877-017-0621-2. [17] By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria? for potentially inappropriate medication use in older adults the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria? for potentially inappropriate medication use in older adults[J]. J Am Geriatr Soc,2019,67(4):674-694. DOI:10.1111/jgs.15767. [18] O’Mahony D, O’Sullivan D, Byrne S, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2[J]. Age Ageing, 2015,44(2):213-218. DOI:10.1093/ageing/afu145. [19] Kadam UT, Roberts I, White S, et al.Conceptualizing multiple drug use in patients with comorbidity and multimorbidity: proposal for standard definitions beyond the term polypharmacy[J]. J Clin Epidemiol,2019,106:98-107. DOI:10.1016/j.jclinepi.2018.10.014. [20] 乔高星, 楚尧娟, 刘冲,等. 2012-2021年潜在不适当用药的研究热点与趋势分析[J]. 中国药房,2023,34(3):370-375. DOI:10.6039/j.issn.1001-0408.2023.03.22. [21] 迟俊婷, 牛晓丹, 阮海慧,等. 老年人潜在不适当用药的评估工具及应用进展[J]. 护理学报,2019, 26(23):36-40. DOI:10.16460/j.issn1008-9969.2019.23.036. [22] Gillette C, Prunty L, Wolcott J, et al.A new lexicon for polypharmacy: implications for research, practice, and education[J]. Res Social Adm Pharm, 2015,11(3):468-471. DOI:10.1016/j.sapharm.2014.08.010. [23] Bitter K, Pehe C, Krüger M, et al.Pharmacist-led medication reviews for geriatric residents in German long-term care facilities[J]. BMC Geriatr,2019, 19(1):39. DOI:10.1186/s12877-019-1052-z. [24] 付洋洋, 陈苏红, 孟美美,等. 医院用药安全多学科协作护理团队运作模式研究进展[J]. 护士进修杂志,2018,33(4):319-322. DOI:10.16821/j.cnki.hsjx.2018.04.008. [25] Krause O, Wiese B, Doyle I M, et al.Multidisciplinary intervention to improve medication safety in nursing home residents: protocol of a cluster randomised controlled trial (HIOPP-3-iTBX study)[J]. BMC Geriatr,2019, 19(1):24. DOI:10.1186/s12877-019-1027-0. [26] 刘畅, 周彬, 徐笑,等. 全国感染防控改进目标信息管理系统的设计与应用[J]. 中国数字医学,2023,18(4):1-7. DOI:10.3969/j.issn.1673-7571.2023.04.001. [27] Woodford H J.Calcium channel blockers co-prescribed with loop diuretics: a potential marker of poor prescribing?[J]. Drugs Aging, 2020,37(2):77-81. DOI:10.1007/s40266-019-00730-4. [28] 王春霞, 贺梦璐, 王海鹏,等. 山东省农村地区多重慢病患者多重用药现状及影响因素分析[J]. 山东大学学报(医学版),2022,60(1):93-100. DOI:10.6040/j.issn.1671-7554.0.2021.0913. [29] Gharekhani A, Somi M, Ostadrahimi A, et al.Prevalence and predicting risk factors of polypharmacy in Azar cohort population[J]. Iran J Pharm Res.2022,21(1):e126922. DOI:10.5812/ijpr-126922. [30] 李荔, 李莎, 卫芸,等. 社区老年人多重用药率及其相关因素的系统综述[J]. 中国全科医学,2021,24(25):3161-3170. DOI:10.12114/j.issn.1007-9572.2021.00.204. [31] 王永利, 栾文艳, 郭亚雯,等. 居家老年多病共存患者多重用药体验的质性研究[J]. 中国全科医学, 2020,23(17):2197-2202. DOI:10.3969/j.issn.1008-9993.2014.22.001. [32] Arabyat RM, Alazzam OM, Al-Azzam SI, et al.Association between charlson comorbidity index and polypharmacy: a retrospective database study from Jordan[J]. Int J Pharm Pract.2021,29(6):580-586. DOI:10.1093/ijpp/riab067. [33] Diaconu CC, Cozma MA, Dobric EC, et al.Polypharmacy in the management of arterial hypertension-friend or foe?[J]. Medicina(Kaunas), 2021,57(12):1288.DOI:10.3390/medicina57121288. [34] Stafford G, Villen N, Roso-Llorach A, et al.Combined multimorbidity and polypharmacy patterns in the elderly: a cross-sectional study in primary health care[J]. Int J Environ Res Public Health, 2021, 18(17):9216. DOI:10.3390/ijerph18179216. [35] Veehof L, Stewart R, Haaijer-Ruskamp F, et al.The development of polypharmacy.A longitudinal study[J].Fam Pract,2000,17(3):261-267. DOI:10.1093/fampra/17.3.261. [36] Pereira KG, Peres MA, Iop D, et al.Polypharmacy among the elderly: a population-based study[J]. Rev Bras Epidemiol,2017, 20(2):335-344.DOI:10.1590/1980-5497201700020013. [37] 吴汀溪, 邢云利, 黄凤,等. 老年多重用药住院患者的用药现状评估及药师干预效果评价[J].中国药房,2019,30(22):3150-3154. DOI:10.6039/j.issn.1001-0408.2019.22.25. [38] 费春晓. 老年共病患者多重用药与肾损伤的相关性研究[D]:青岛:青岛大学,2020.DOI:10.27262/d.cnki.gqdau.2020.001145. [39] 李凤,王建华, 宋开兰. 老年病人多重用药的研究进展[J]. 护理研究,2020, 34(23):4207-4210. DOI:10.12102/j.issn.1009-6493.2020.23.019. [40] Veronese N, Stubbs B, Noale M, et al.Polypharmacy is associated with higher frailty risk in older people: an 8-year longitudinal cohort study[J]. J Am Med Dir Assoc,2017,18(7):624-628. DOI:10.1016/j.jamda.2017.02.009. [41] Dhalwani NN, Fahami R, Sathanapally H, et al.Association between polypharmacy and falls in older adults: a longitudinal study from England[J].BMJ Open,2017,7(10):e016358. DOI:10.1136/bmjopen-2017-016358. [42] Sganga F, Landi F, Ruggiero C, et al.Polypharmacy and health outcomes among older adults discharged from hospital: results from the CRIME study[J]. Geriatr Gerontol Int,2015,15(2):141-146. DOI:10.1111/ggi.12241. [43] Brockhattingen KK, Anru PL, Masud T, et al.Association between number of medications and mortality in geriatric inpatients: a Danish nationwide register-based cohort study[J]. Eur Geriatr Med,2020,11(6):1063-1071. DOI:10.1007/s41999-020-00390-3. [44] Vicente S, Olmos-Jiménez R, Ramírez-Roig C, et al.Treatment adherence in patients older than 65 years who suffer early readmissions[J]. Farm Hosp, 2018,42(4):147-151. DOI:10.7399/fh.10907. [45] 李晨. 老年住院患者多重用药干预体系构建[D].北京:中国人民解放军医学院,2019.DOI:10.27637/d.cnki.gjyjc.2019.000135. [46] 廖雅慧, 郎驿天, 林燕,等. 常用老年人潜在不适当用药判断标准比较[J]. 中国药房,2022,33(9):1131-1135. DOI:10.6039/j.issn.1001-0408.2022.09.18. [47] 刘夏, 潘琴, 徐迅科,等. 基于《中国老年人潜在不适当用药判断标准(2017版)》的老年患者不适当用药评价研究[J]. 药学实践杂志,2019,37(3):283-288. DOI:10.3969/j.issn.1006-0111.2019.03.019. [48] 黄静, 蔡娟娟, 吴伦. 老年内分泌疾病患者的潜在不适当用药及影响因素分析[J]. 中国医院药学杂志,2023,43(4):431-435. DOI:10.13286/j.1001-5213.2023.04.15. [49] 何梅, 邵鑫, 赵曜,等. Beers标准、STOPP/START标准及中国PIM初级判断标准评价某院心血管内科医嘱的对比研究[J]. 中国医院药学杂志,2018,38(7):781-784+791. DOI:10.13286/j.cnki.chinhosppharmacyj.2018.07.21. [50] 尹茜, 曹立. 1例老年人急性期照护单元老年患者多重用药分析[J]. 医药导报,2022,41(3):406-409. DOI:10.3870/j.issn.1004-0781.2022.03.024. |
| [1] | YANG Zhong-shan, XU Ni-na, ZHAN Yu-xin, LIU Ning, LI Zhao-hui, LE Ge-fen. Summary of Best Evidence for Standardized Management of Physical Restraint in Inpatients [J]. Journal of Nursing, 2019, 26(4): 31-36. |
|